Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Non-cash Items (2020 - 2024)

Historic Non-cash Items for Apellis Pharmaceuticals (APLS) over the last 5 years, with Q4 2024 value amounting to $6.7 million.

  • Apellis Pharmaceuticals' Non-cash Items fell 9735.64% to $6.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $6.7 million, marking a year-over-year decrease of 9735.64%. This contributed to the annual value of $6.7 million for FY2024, which is 9735.64% down from last year.
  • As of Q4 2024, Apellis Pharmaceuticals' Non-cash Items stood at $6.7 million, which was down 9735.64% from $253.9 million recorded in Q4 2023.
  • Over the past 5 years, Apellis Pharmaceuticals' Non-cash Items peaked at $317.0 million during Q4 2022, and registered a low of $6.1 million during Q4 2020.
  • Moreover, its 5-year median value for Non-cash Items was $253.9 million (2023), whereas its average is $175.1 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first soared by 471400.53% in 2021, then tumbled by 9735.64% in 2024.
  • Apellis Pharmaceuticals' Non-cash Items (Quarter) stood at $6.1 million in 2020, then soared by 4714.01% to $291.8 million in 2021, then increased by 8.64% to $317.0 million in 2022, then fell by 19.9% to $253.9 million in 2023, then crashed by 97.36% to $6.7 million in 2024.
  • Its last three reported values are $6.7 million in Q4 2024, $253.9 million for Q4 2023, and $317.0 million during Q4 2022.